Medical toxicology and adverse drug experience最新文献

Fulminant hyperkalaemia and multiple complications following ibuprofen overdose. 过量布洛芬后暴发性高钾血症和多种并发症。

Medical toxicology and adverse drug experience Pub Date : 1989-11-01 DOI: 10.1007/BF03259927

D G Menzies, A G Conn, I J Williamson, L F Prescott

引用次数: 15

Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide. 1B类抗心律失常药物引起的中毒。利多卡因，美西汀和托卡因胺。

Medical toxicology and adverse drug experience Pub Date : 1989-11-01 DOI: 10.1007/BF03259923

C P Denaro, N L Benowitz

{"title":"Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.","authors":"C P Denaro, N L Benowitz","doi":"10.1007/BF03259923","DOIUrl":"https://doi.org/10.1007/BF03259923","url":null,"abstract":"Since most of the toxicity associated with class 1B antiarrhythmic drugs is dose-related, this review examines adverse effects seen in both therapeutic practice and accidental or premeditated overdose. Toxicity is very common with these agents and can be life-threatening. A high percentage of patients must discontinue therapy because of adverse effects. Mexiletine and tocainide are structural analogues of lignocaine (lidocaine) and toxicity is similar with all 3 drugs. With gradual intoxication (the most common form) central nervous system effects such as lightheadedness, dizziness, drowsiness and confusion are seen first. Seizures and respiratory arrest can occur. Cardiovascular toxicity is manifested by progressive heart block, reduced cardiac contraction, hypotension and asystole. Both mexiletine and tocainide may have proarrhythmic effects. Gastrointestinal toxicity is also common. Shock, hypotension, cardiac failure and beta-blocker therapy reduce lignocaine clearance and enhance the risk of intoxication during routine therapy. Both lignocaine and mexiletine elimination is impaired in severe liver disease while tocainide clearance is reduced in renal failure. Management of toxicity is largely supportive and symptomatic. Lignocaine infusion must be discontinued and decontamination of the gut in the case of oral preparations is recommended. Serious intoxication requires intensive care unit admission. Haemodialysis or haemoperfusion may be helpful in serious lignocaine and tocainide poisoning. In institutions where extracorporeal circulatory assistance is available, massive lignocaine poisoning has been successfully treated with this intervention. In the therapeutic setting serious toxicity can be prevented by close clinical surveillance and appropriate dose reduction in patients with reduced drug clearance. Because of the large interindividual variation in lignocaine pharmacokinetic parameters, therapeutic drug monitoring is recommended if results can be reported quickly. Mexiletine and tocainide have stereoselective metabolism and assays do not distinguish the more active isomers. Therapeutic drug monitoring is less useful in this situation.","PeriodicalId":77748,"journal":{"name":"Medical toxicology and adverse drug experience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1989-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF03259923","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13658073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs? 延长的QTc间隔。这是抗心律失常药物的重要作用吗?

Medical toxicology and adverse drug experience Pub Date : 1989-11-01 DOI: 10.1007/BF03259922

F A Fish, D M Roden

引用次数: 6

A review of the Redman syndrome and rifampicin overdosage. 雷德曼综合征与利福平过量的研究进展。

Medical toxicology and adverse drug experience Pub Date : 1989-11-01 DOI: 10.1007/BF03259925

M R Holdiness

{"title":"A review of the Redman syndrome and rifampicin overdosage.","authors":"M R Holdiness","doi":"10.1007/BF03259925","DOIUrl":"https://doi.org/10.1007/BF03259925","url":null,"abstract":"The literature was reviewed for cases of cutaneous pigmentation induced by rifampicin overdosage. 29 examples have been described, in which 2 general groups of individuals were observed. The first consisted of older individuals (average age 27.1 years) who attempted suicide. A prior history of suicide attempts, depression and substance abuse was a predominant factor in these patients. The second group included generally younger patients (average age 2.9 years) in whom misformulation of rifampicin preparations for treatment of Haemophilus influenzae Type B resulted in bright reddish-orange discoloration to the skin. The time to clinical appearance of skin discoloration was approximately 2.2 hours after administration. Periorbital or facial oedema occurred in 72.4% of the patients, pruritus in 62.1% and either nausea, vomiting or diffuse abdominal tenderness in 51.7%. Limited laboratory data are available but these indicate that all patients had elevated levels of total bilirubin. Histological examination in selected individuals revealed rifampicin crystal deposits in the nasopharynx, gastrointestinal tract and lining of the aorta. In adults, it appears that a dose of at least 14 g of rifampicin is necessary before cardiovascular-pulmonary arrest occurs. Other than general supportive measures, very few methods are described in the literature for the treatment of acute intoxications with this drug. A differential diagnosis of other causes of reddish-orange pigmentation is discussed, together with clinical information to differentiate these cases from toxic rifampicin ingestion.","PeriodicalId":77748,"journal":{"name":"Medical toxicology and adverse drug experience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1989-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF03259925","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13830170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Drug-induced ototoxicity. Pathogenesis and prevention. 药物引起的耳毒性。发病机制和预防。

Medical toxicology and adverse drug experience Pub Date : 1989-11-01 DOI: 10.1007/BF03259926

M Y Huang, J Schacht

{"title":"Drug-induced ototoxicity. Pathogenesis and prevention.","authors":"M Y Huang, J Schacht","doi":"10.1007/BF03259926","DOIUrl":"https://doi.org/10.1007/BF03259926","url":null,"abstract":"Ototoxicity is a disabling adverse effect of several widely used classes of drugs, such as diuretics, anti-inflammatory agents, antineoplastic agents and aminoglycoside antibiotics. High-dose therapy with either diuretics or anti-inflammatory agents is primarily associated with acute and transient impairment of hearing or tinnitus. In contrast, long term treatment with antineoplastic agents or aminoglycoside antibiotics is typically associated with delayed and irreversible loss of hearing; lesion in the organ of Corti include the destruction of auditory sensory cells. Vestibular function can also be compromised by ototoxic drugs. Occasional cases of ototoxicity have been reported for a variety of other therapeutic compounds and environmental toxins. In addition, the simultaneous administration of multiple agents which are potentially ototoxic can lead to synergistic loss of hearing. Exposure to loud noise may also potentiate the hearing loss due to cochleotoxic drugs. Ototoxic agents can impair the sensory processing of sound at many cellular or subcellular sites. However, the molecular mechanisms of ototoxicity have not been established for most of these drugs, and structure-toxicity relationships have not been determined. It has therefore been difficult to predict the ototoxic potential of new drugs, and rational approaches to the prevention of ototoxicity are still lacking. The clinical and experimental features of ototoxicity are reviewed for several classes of drugs, with an emphasis on current knowledge of the mechanism and the possibilities for the prevention of ototoxicity for each.","PeriodicalId":77748,"journal":{"name":"Medical toxicology and adverse drug experience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1989-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF03259926","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13831588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

Problems and pitfalls in the use of hyperbaric oxygen for the treatment of poisoned patients. 高压氧治疗中毒病人的问题和隐患。

Medical toxicology and adverse drug experience Pub Date : 1989-11-01 DOI: 10.1007/BF03259921

D F Gorman

引用次数: 10

Clinical features and management of poisoning due to potassium chloride. 氯化钾中毒的临床特点及处理。

Medical toxicology and adverse drug experience Pub Date : 1989-11-01 DOI: 10.1007/BF03259924

K Saxena

{"title":"Clinical features and management of poisoning due to potassium chloride.","authors":"K Saxena","doi":"10.1007/BF03259924","DOIUrl":"https://doi.org/10.1007/BF03259924","url":null,"abstract":"Potassium is one of the most abundant ions in the human body and yet it is difficult to assess potassium balance. Potassium chloride is extensively used as a potassium supplement, both by physicians as a therapeutic modality and by the general public, mostly in the form of salt substitute. Therapeutically, both the oral and intravenous forms of potassium are utilised. Overdose of potassium is not as frequently encountered in clinical practice as hyperkalaemia (excess potassium in the body) due to acute or chronic renal disease. Potassium homeostasis is maintained very delicately and is governed by the daily consumption of potassium and the renal excretion mechanisms. Any change in these or related factors can present as hyperkalaemia. However, potassium overdoses leading to serious consequences do occur. Orally, the dose of potassium has to be large enough so that the normal excretory mechanisms for potassium are overcome and clinical toxicity occurs. It takes a much bigger dose of ingested potassium to produce toxicity in a person with normal renal function than in patients with compromised renal function. Potassium toxicity manifests in significant, characteristic, acute cardiovascular changes with ECG abnormalities. Besides cardiovascular effects, neuromuscular manifestations in the form of general muscular weakness and ascending paralysis occur. Gastrointestinal symptoms manifest as nausea, vomiting, paralytic ileus, and local mucosal necrosis which may lead to perforation. It is imperative when treating hyperkalaemia that the whole clinical picture is taken into account rather than the numerical potassium values. Only the extracellular potassium can be measured in the laboratory, yet 98% of the body potassium is intracellular and cannot be measured. In acute overdose situations due to ingestion of potassium salt, the general principles of treatment for overdoses should be followed. Calcium chloride infusion, dextrose and insulin in water, and correction of acidosis with sodium bicarbonate are helpful in controlling the acute, life-threatening cardiac arrhythmias. These modalities do not remove the excess potassium from the body. That is achieved either by utilising ion-exchange resins or by mechanically removing potassium via haemodialysis. To curtail inadvertent or accidental potassium overdoses, physicians should prescribe any potassium supplements very carefully to their patients and monitor the plasma potassium periodically.","PeriodicalId":77748,"journal":{"name":"Medical toxicology and adverse drug experience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1989-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF03259924","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13830168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

Pharmacokinetics and toxicity of bismuth compounds. 铋化合物的药代动力学和毒性。

Medical toxicology and adverse drug experience Pub Date : 1989-09-01 DOI: 10.1007/BF03259915

A Slikkerveer, F A de Wolff

{"title":"Pharmacokinetics and toxicity of bismuth compounds.","authors":"A Slikkerveer, F A de Wolff","doi":"10.1007/BF03259915","DOIUrl":"https://doi.org/10.1007/BF03259915","url":null,"abstract":"Inorganic bismuth salts are poorly soluble in water: solubility is influenced by the acidity of the medium and the presence of certain compounds with (hydr)oxy or sulfhydryl groups. The analysis of bismuth in biological material is not standardised and is subject to large variation; it is difficult to compare data from different studies, and older data should be approached with caution. The normal concentration of bismuth in blood is between 1 and 15 micrograms/L, but absorption from oral preparations produces a significant rise. Distribution of bismuth in the organs is largely independent of the compound administered or the route of administration: the concentration in kidney is always highest and the substance is also retained there for a long time. It is bound to a bismuth-metal binding protein in the kidney, the synthesis of which can be induced by the metal itself. Elimination from the body takes place by the urinary and faecal routes, but the exact proportion contributed by each route is still unknown. Elimination from blood displays multicompartment pharmacokinetics, the shortest half-life described in humans being 3.5 minutes, and the longest 17 to 22 years. A number of toxic effects have been attributed to bismuth compounds in humans: nephropathy, encephalopathy, osteoarthropathy, gingivitis, stomatitis and colitis. Whether hepatitis is a side effect, however, is open to dispute. Each of these adverse effects is associated with certain bismuth compounds. Bismuth encephalopathy occurred in France as an epidemic of toxicity and was associated with the intake of inorganic salts including bismuth subnitrate, subcarbonate and subgallate. In the prodromal phase patients developed problems in walking, standing or writing, deterioration of memory, changes in behaviour, insomnia and muscle cramps, together with several psychiatric symptoms. The manifest phase started abruptly and was characterised by changes in awareness, myoclonia, astasia and/or abasia and dysarthria. Patients recovered spontaneously after discontinuation of bismuth. Intestinal lavage, forced diuresis and haemodialysis have been tried without positive effects on the clinical condition of the patient or on blood bismuth concentration, and the use of dimercaprol as an antidote has produced reports of both positive and negative findings. To confirm the diagnosis of bismuth encephalopathy, it is essential to find elevated bismuth concentrations in blood, plasma, serum or CSF. A safety level of 50 micrograms/L and an alarm level of 100 micrograms/L have been suggested in the past, but no proof is available to support the choice of these levels.(ABSTRACT TRUNCATED AT 400 WORDS)","PeriodicalId":77748,"journal":{"name":"Medical toxicology and adverse drug experience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1989-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF03259915","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13823799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 215

Recurrent poisonings among paediatric poisoning victims. 儿童中毒受害者中的反复中毒。

Medical toxicology and adverse drug experience Pub Date : 1989-09-01 DOI: 10.1007/BF03259919

T L Litovitz, S L Flagler, A S Manoguerra, J C Veltri, L Wright

{"title":"Recurrent poisonings among paediatric poisoning victims.","authors":"T L Litovitz, S L Flagler, A S Manoguerra, J C Veltri, L Wright","doi":"10.1007/BF03259919","DOIUrl":"https://doi.org/10.1007/BF03259919","url":null,"abstract":"A study of 1943 potentially toxic ingestions occurring in children under 6 years of age was conducted by 3 geographically and demographically diverse poison centres to determine the incidence of exposures to poison. Of the total group, 30.1% indicated that the child had experienced a prior poison exposure (12.0% in children under 1 year of age, and 41.3% of children between the ages of 3 and 5 years). Most repeaters (68.9%) experienced only 1 prior ingestion (range 1 to 15). Two prior ingestions were reported in 17.6% of repeaters; 3 prior ingestions in 4.4%. A profound effect of age on type of substance ingested was observed, with drugs accounting for 11.0% of ingestions in children under the age of 1 year, 23.2% in 1-year-old, and 49.9% in 2- to 5-year-old. A corresponding age-related decline in ingestions of household and personal care products was also noted. Although less marked than the age effect, a statistically significant propensity to re-ingest similar types of poisons was observed. Among repeaters, those with a prior ingestion of a drug subsequently ingested another drug 1.49 times more frequently than expected. A similar trend was observed with products (1.24 times more frequently) and plants (2.00 times more frequently).","PeriodicalId":77748,"journal":{"name":"Medical toxicology and adverse drug experience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1989-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF03259919","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13951125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

Management of dapsone poisoning complicated by methaemoglobinaemia. 氨苯砜中毒并发甲基血红蛋白血症的处理。

Medical toxicology and adverse drug experience Pub Date : 1989-09-01 DOI: 10.1007/BF03259920

A H Dawson, I M Whyte

引用次数: 28